Test drug VGA039 for bleeding control in von Willebrand disease
Part of Blood & lymphatic, Genetic & congenital, Heart & circulation clinical trials.
This Phase 1/2 study tests VGA039 in healthy adults and people with von Willebrand disease (VWD). The goal is to see if the drug is safe and how it affects bleeding-related factors, especially in people who have symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are within the study age range (18–60 for some parts; 12–60 for other parts).
- Your blood tests, heart tracing (ECG), and vital signs (like blood pressure) are not significantly abnormal.
- If you’re in the VWD patient parts, you have a history of bleeding or bruising and your hemoglobin is at least 8 g/dL and platelets at least 150.
- You must not have certain inherited clotting problems (like FV Leiden or related conditions) found on screening tests.
- You cannot have a past history of blood clots (arterial or venous), including serious clot-related events.
- You must not have certain major organ or body system diseases (kidney, liver, brain/nerve, lung, heart/vessels, or uncontrolled metabolic problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a Von Willebrand disease treatment plan works during pregnancy, and whether some patients need extra “adjusting” of medicine. It may help prevent bleeding problems by matching treatment to each person’s lab results later in pregnancy.
This study uses special video imaging to try to predict when bleeding may happen in certain inherited bleeding disorders. It may help doctors better anticipate bleeding and guide safer care.
This study looks at cardiovascular problems and blood-clot events (like deep vein clots or pulmonary embolism) in adults with Von Willebrand disease in western France. It may help doctors better understand who is at risk and how to manage these complications.
This trial tests a new medicine called ALN-6400 in teenage and adult women with von Willebrand disease (a blood clotting condition) who experience heavy menstrual bleeding. The goal is to see if this treatment can reduce bleeding and improve quality of life.
This Phase 1 trial studies how well and safely emicizumab works for people with severe von Willebrand disease (VWD) or VWD plus hemophilia A. Emicizumab is a preventive medicine given regularly to reduce bleeding risk.
This trial tests a new drug called VGA039 that is injected under the skin to prevent bleeding episodes in people with von Willebrand disease. It is for those who bleed frequently and are not currently using regular preventive treatments.
Hear when a new Von Willebrand Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.